AKT1 and colonic neoplasm: Research has shown that in a combinational therapy containing BEZ235, a relatively new inhibitor of the PI3K/Akt/mTOR pathway, and the chemotherapeutic 5-FU, BEZ235 sensitized the HCT-116 colon cancer cells to 5-FU-induced apoptosis [70].